ID
× COMMENTARYCOVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More
Chemical Engineering MagazineCO2-to-methanol
Researchers from Penn State University (State College, Pa.; www.psu.edu) and…
Chemical Engineering MagazineChementator Briefs
Bio-isoprene Yokohama Rubber Co. (Tokyo, Japan; www.yokohama.com) has developed what…
BUSINESS NEWSTECHNICAL & PRACTICALFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILEENGINEERING PRACTICEENVIRONMENTAL MANAGEREQUIPMENT & SERVICESFOCUSNEW PRODUCTS + Show More SHOW PREVIEWS

Comment

Lonza announces new biomanufacturing complex in Switzerland

By Mary Page Bailey |

Lonza Group AG (Basel, Switzerland; www.lonza.com) has launched the latest addition to its current biological manufacturing capabilities. Ibex Solutions is an innovative biological development and manufacturing concept, coupling flexibility in facility build-out with fully tailored business models and leveraging Lonza’s expertise and service network in Visp, Switzerland. Construction began in June 2017, with a formal groundbreaking ceremony expected in the second half of 2017. Several hundred new positions are expected to be created.

Ibex biomanufacturing comprises a modular, technology-independent development and manufacturing complex capable of supporting activities across multiple technologies – mammalian, microbial, cellular or bio-conjugate – and from late discovery to manufacture. This flexibility gives customers complete freedom in facility design and implementation, and the ability to respond rapidly as their needs evolve.

Responsiveness is further enhanced by the integration of the Ibex biomanufacturing complex into the Visp site with its experienced workforce and established service networks.

Ibex Solutions include highly flexible models to match and adapt to each customer’s expectations and forecasts. The availability of a modular complex means time-to-market can be reduced by 12 months or more. These advantages contribute to a significant de-risking of major strategic investment decisions.

Lonza’s Pharma & Biotech COO, Marc Funk, commented: “Lonza has been creating innovative manufacturing and production solutions for 120 years, and we are continuing to pioneer clinical and commercial manufacturing in multiple technologies all over the world. We have been working with our partners to understand what we can offer that will really change the game for them, and that’s why we have created Ibex.”

Related Content
Interphex 2018 Show Preview
Interphex, the annual event focused on pharmaceutical and biotechnology manufacturing, takes place April 17–19 at the Jacobs Javits Center in…

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Simplify sensor handling and maintenance with ISM
Three reasons to measure pH in-line
ABB Ability™ technology to transform BASF rotating equipment into intelligent machinery and improve uptime and reliability
Detect and correct anomalies early in your batch processes
ABB at ACHEMA 2018

View More

Live chat by BoldChat